Gilberto Quintero
Organogenesis HoldingsAbout Gilberto Quintero
Gilberto Quintero, age 60, has served on Organogenesis Holdings Inc.’s board since 2022 and is classified as an independent director; he is a member of the Audit Committee and not a committee chair . He is Global Chief Quality Officer at Kimberly‑Clark Corporation (NYSE: KMB) since 2019, previously Chief Quality & Regulatory Affairs Officer for Pharmaceuticals and Medical Devices at Cardinal Health (NYSE: CAH) from 2015–2019, with 11 years prior at Wyeth/Pfizer in technical leadership roles across R&D, Quality, and Technical Operations . His education includes a PhD in Chemistry (Texas A&M University), an MBA (University of Tennessee at Chattanooga), and a BS in Chemistry (Catholic University of Puerto Rico), positioning him as a quality and regulatory specialist with deep healthcare manufacturing context . In 2025 he was re‑elected by shareholders, receiving 72,402,755 votes for and 1,056,310 withheld, indicating broad investor support .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Cardinal Health, Inc. (NYSE: CAH) | Chief Quality & Regulatory Affairs Officer, Pharmaceuticals & Medical Devices | 2015–2019 | Led quality/regulatory oversight in large-scale healthcare distribution/manufacturing |
| Wyeth/Pfizer | Technical leadership roles in R&D, Quality, Technical Operations | 11 years (dates not individually specified) | Advanced technical operations and quality systems in pharma contexts |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Kimberly‑Clark Corporation (NYSE: KMB) | Global Chief Quality Officer | 2019–present | Senior leadership across global quality management |
Board Governance
- Committee assignments: Audit Committee member; Audit Committee chaired by Arthur S. Leibowitz; members include Prathyusha Duraibabu, Jon Giacomin, and Quintero; all satisfy Nasdaq and SEC independence standards and financial literacy requirements .
- Independence: Quintero is explicitly designated an independent director under the board’s compensation program and Nasdaq rules .
- Attendance and engagement: Board met seven times in FY2024; no director (other than Alan A. Ades) attended fewer than 75% of meetings and committee meetings—Quintero thus met attendance expectations; Audit Committee met six times in FY2024 .
- Years of service: Director since 2022 .
- Leadership context: Board combines Chair/CEO roles; Lead Independent Director is Arthur S. Leibowitz, who presides over executive sessions of independent directors .
- Shareholder support: Re‑elected at the 2025 Annual Meeting (votes for 72,402,755; withheld 1,056,310) .
Fixed Compensation
| Component | Amount (FY2024) | Notes |
|---|---|---|
| Annual Director Retainer (cash) | $55,000 | Independent directors receive $55,000 cash retainer |
| Audit Committee Member Fee | $10,000 | Non‑chair audit members receive $10,000 |
| Total Cash Earned | $65,000 | Quintero’s FY2024 director cash fees totaled $65,000 |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Grant Date Fair Value | Vesting/Key Terms |
|---|---|---|---|---|
| RSUs (Independent Director Annual Grant) | Feb 2024 | 51,020 | $175,000 | Time‑based; vested on or about Feb 15, 2025, subject to continued service |
| Options | N/A | None | N/A | No options outstanding for Quintero as of Dec 31, 2024 |
| Director Change‑in‑Control Agreement | N/A | N/A | N/A | Full acceleration of vesting of any time‑based equity awards upon serving immediately prior to a Change in Control |
No performance metrics (e.g., TSR, revenue, EBITDA) are tied to director equity grants; awards are time‑vested per policy .
Other Directorships & Interlocks
| Company | Role | Committee Roles | Notes |
|---|---|---|---|
| None disclosed | — | — | No other public company board memberships disclosed for Quintero . |
Expertise & Qualifications
- Quality and regulatory leadership across global consumer health and medical products, with executive roles at Kimberly‑Clark and Cardinal Health .
- Technical depth in pharma operations from Wyeth/Pfizer across R&D, Quality, Technical Operations .
- Advanced academic credentials (PhD Chemistry; MBA; BS Chemistry) supporting oversight of compliance, risk controls, and manufacturing quality .
Equity Ownership
| Metric | Amount | Notes |
|---|---|---|
| Beneficial Ownership (as of Apr 11, 2025) | 140,670 shares; <1% | Reported in proxy beneficial ownership table |
| Options Outstanding | None | No options listed for Quintero in 12/31/2024 director awards table |
| RSUs Outstanding (12/31/2024) | 51,020 units | Annual director grant; subsequently vested Feb 15, 2025 |
- Pledging/Hedging: Insider Trading Policy prohibits short sales, hedging, publicly traded options, and purchasing Company securities on margin; no pledging disclosed for Quintero in the proxy .
- Ownership guidelines: Director stock ownership guidelines are not disclosed in the proxy .
Governance Assessment
- Strengths: Independent director with deep domain expertise in quality/regulatory matters; sits on Audit Committee responsible for financial reporting oversight, compliance, and related‑party transaction approvals—supportive of board effectiveness and risk oversight .
- Attendance/engagement: Met Board attendance thresholds; Audit Committee met six times in FY2024, indicating active committee engagement .
- Investor confidence: Strong re‑election vote at 2025 Annual Meeting (72.4M votes for), and say‑on‑pay support historically robust (92% approval at 2024 meeting for executive pay), signaling positive investor sentiment toward governance; 2025 say‑on‑pay also approved .
- Compensation alignment: Director cash pay modest ($65k) with predominant equity via time‑vested RSUs ($175k), plus change‑in‑control acceleration of time‑based vesting—standard alignment mechanism without high‑risk incentives .
- Conflicts/related‑party exposure: Proxy discloses related‑party leases and repurchases involving the Significant Stockholder Group (Ades/Erani/Nussdorf), but no transactions involve Quintero; Audit Committee (including Quintero when disinterested) oversees these, mitigating conflict risks .
- RED FLAGS: None disclosed specific to Quintero—no Section 16(a) filing issues, no hedging/pledging indicated, no related‑party transactions tied to him .
Insider Filings Snapshot
| Item | Status | Notes |
|---|---|---|
| Section 16(a) Filings (FY2024) | Compliant | Company states directors complied with applicable filing requirements in FY2024 |
For individual Form 4 transaction details, refer to SEC Section 16 filings; no transaction list is provided in the proxy .
Related-Party Transactions Context (Board Oversight)
- Significant Stockholder Group lease arrangements at Dan Road facilities (payments and terms disclosed) reviewed under the related‑party transaction policy; Audit Committee (disinterested members) reviews/approves .
- November 2024 repurchase agreements with certain stockholders (including Nussdorf and Ades affiliates) were approved by the Audit Committee and a Transaction Committee; funded in part by proceeds from the Convertible Preferred private placement .
- Quintero is not named as a party to these related‑party transactions .
Compensation Committee Practices (Context)
- Compensation Committee is fully independent and engages Pearl Meyer as independent consultant; added PSUs for executives in 2025, indicating evolution toward performance‑linked equity (contextual governance quality) .
- Say‑on‑pay received strong support historically (92% in 2024), reflecting shareholder approval of pay practices managed by the committee .